McKesson (NYSE:MCK) Updates FY 2027 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of 43.800-44.600 for the period, compared to the consensus earnings per share estimate of 44.130. The company issued revenue guidance of -.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley restated an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a report on Thursday, January 29th. Robert W. Baird set a $968.00 price objective on shares of McKesson in a report on Wednesday, January 14th. Bank of America reduced their price objective on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating on the stock in a report on Monday, April 6th. JPMorgan Chase & Co. raised their price objective on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Finally, TD Cowen lifted their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research note on Thursday, February 5th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $972.27.

McKesson Trading Up 1.3%

NYSE:MCK traded up $9.76 during midday trading on Thursday, hitting $753.43. 2,019,691 shares of the company were exchanged, compared to its average volume of 882,212. The company has a fifty day simple moving average of $883.74 and a 200 day simple moving average of $859.93. McKesson has a fifty-two week low of $637.00 and a fifty-two week high of $999.00. The company has a market capitalization of $92.29 billion, a PE ratio of 21.67, a price-to-earnings-growth ratio of 1.07 and a beta of 0.35.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $96.30 billion for the quarter, compared to analyst estimates of $101.35 billion. During the same period last year, the business earned $10.12 EPS. McKesson’s revenue for the quarter was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. As a group, equities research analysts expect that McKesson will post 39.02 EPS for the current year.

McKesson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be paid a $0.82 dividend. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s payout ratio is currently 9.43%.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the transaction, the executive vice president directly owned 3,247 shares in the company, valued at approximately $3,214,530. The trade was a 45.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Maria Martinez sold 349 shares of McKesson stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the transaction, the director owned 301 shares in the company, valued at approximately $282,900.87. This represents a 53.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 3,592 shares of company stock valued at $3,518,555. Company insiders own 0.08% of the company’s stock.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q4 EPS topped estimates — McKesson reported $11.69/share versus a $11.56 consensus, showing earnings beat versus expectations. This helped calm near?term sentiment after recent sector volatility. Read More.
• Positive Sentiment: FY?2027 guidance centered on EPS 43.80–44.60, a range whose midpoint is roughly at/just above consensus; management pointed to strength in oncology and specialty drug distribution as the driver. That forward outlook reduced downside surprise risk. Read More.
• Positive Sentiment: Management reaffirmed long?term financial targets and highlighted growth areas (oncology, GLP?1/biopharma services), giving investors a strategic growth narrative beyond the quarter. Read More.
• Neutral Sentiment: Company made full earnings materials (press release, slide deck, webcast) available for investors to review — useful for digging into segment trends and guidance assumptions. Read More.
• Neutral Sentiment: Coverage pieces on McKesson’s strategic moves (AI initiatives, reshaping care delivery) are longer?term positives but unlikely to move the stock near term compared with the earnings print. Read More.
• Negative Sentiment: Revenue missed expectations — Q4 revenue was ~$96.3B vs. analyst estimates near $101.4B, which may signal softer volume or pricing dynamics in portions of the business. Read More.
• Negative Sentiment: Profitability metrics are a concern: reported net margin was low (~1.09%) and return on equity was negative (driven by accounting impacts), which can temper enthusiasm despite the EPS beat. Read More.
• Negative Sentiment: Sector?wide pre?earnings weakness and recent insider/institutional selling amplified volatility into the print — investors had partially de?risked ahead of results, which can increase short?term price swings. Read More.

Institutional Trading of McKesson

Hedge funds and other institutional investors have recently made changes to their positions in the company. Brighton Jones LLC boosted its holdings in shares of McKesson by 46.3% in the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after acquiring an additional 798 shares in the last quarter. Sivia Capital Partners LLC boosted its holdings in shares of McKesson by 77.9% in the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock valued at $502,000 after acquiring an additional 300 shares in the last quarter. Wescott Financial Advisory Group LLC purchased a new stake in shares of McKesson in the fourth quarter valued at about $202,000. Wealth Watch Advisors INC purchased a new stake in shares of McKesson in the third quarter valued at about $180,000. Finally, Triumph Capital Management purchased a new stake in shares of McKesson in the third quarter valued at about $179,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.